Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jun;57(11):1343-1344.
doi: 10.1111/apt.17490.

Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease-time for universal recommendation?

Fabio Salvatore Macaluso  1 , Ambrogio Orlando  1
Affiliations
Editorial

Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease-time for universal recommendation?

Fabio Salvatore Macaluso et al. Aliment Pharmacol Ther. 2023 Jun.
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

REFERENCES

    1. Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:420-9.
    1. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-population-based survey. J Pain. 2005;6:356-63.
    1. Anderson TC, Masters NB, Guo A, Shepersky L, Leidner AJ, Lee GM, et al. Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: recommendations of the Advisory Committee on Immunization Practices-United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:80-4.
    1. Caldera F, Spaulding AC, Borah B, Moriarty J, Zhu Y, Hayney MS, et al. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease. Aliment Pharmacol Ther. 2023;57:1326-34. https://doi.org/10.1111/apt.17454
    1. Gialouri CG, Moustafa S, Thomas K, Hadziyannis E, Vassilopoulos D. Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies. Rheumatol Int. 2023;43:421-35.

Substances